₹1.5 lakh cancer drug scam exploits desperate patients
Fixers reuse vials, fake Keytruda cheats cancer patients
Punjab’s quiet countryside hides a story that could belong to any Indian family: a modest house, a middle‑aged woman, and a word that has changed everything—“cancer.” In early 2022, a 56‑year‑old woman near Chandigarh walked into the Postgraduate Institute of Medical Education and Research (PGIMER) for treatment of liver cancer. Her world narrowed to hospital corridors, blood reports, and the dry, technical term her doctors used: Keytruda, an immunotherapy drug made by Merck & Co (MSD). It was, they said, one of her best chances.
Keytruda is one of the most powerful and expensive cancer drugs in the world. In India, an official 100 mg vial costs upwards of Rs 1.5 lakh—a price that can equal a working‑class family’s entire savings. For the woman’s children, it was a number that made their stomachs sink. Still, they had to try. Hope, they believed, could not be priced.
Weighed down by the burden, the family turned to the usual escape routes: local medical stores, whispers about “discount” medicines, and the uneasy comfort of paying less than the hospital’s sticker price. Between September and December that year, they bought 12 vials from a local medical shop, paying roughly Rs 16 lakh. The “discount” felt like a small mercy—a sliver of relief in a long, painful journey. They didn’t know then that the vials they were injecting into their mother’s veins were not Keytruda at all.
Months passed. The treatments continued. Then, a phone call from Delhi. It was the police. The medications they had used were fake. The clear liquid inside the vials was not the life‑saving immunotherapy they had paid for, but an antifungal medication—essentially, the wrong drug for a cancer patient.
The shock was more than financial. It was emotional, ethical, even existential. The family had gambled their savings, homes, and borrowed money to buy what they thought was a cutting‑edge drug. Instead, they had been silently poisoned by a counterfeit product that offered no real fight against cancer. Every injection, every moment of hope, now felt tainted by betrayal.
For the woman, the news was devastating. The disease had already taken much from her—energy, weight, and the simple pleasure of watching her children grow older. Now, even the treatment she trusted had turned into a lie. The family had to ask the hardest questions: had the fake medicine worsened her condition? Had time been stolen from her? Was the medicine that cost them a fortune merely a placebo with side effects?
The story of this Punjab household is not an isolated case. It is a mirror held up to India’s cancer crisis: a rapidly growing number of patients, fragile public‑health systems, and exorbitant drug prices that push families into the arms of black‑market shortcuts. In a country where the middle class still counts every rupee, the line between “affordable” and “attainable” is often crossed with a fake vial. Behind every headline about counterfeit cancer drugs is a family like this one—ordinary, hopeful, and cheated into believing they were doing everything right.